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A normal thyroid function is important for 
growth and neurological development in chil-
dren, and hypothyroidism in childhood is 
accompanied by growth retardation. A grow-
ing number of reports have indicated that 
environmental chemicals can interfere with 
thyroid function [reviewed by Boas et al. 
(2006)]. Both experimental and observa-
tional studies of wildlife and humans have 
suggested specific chemicals to have thyroid-
disrupting properties, including recent inves-
tigations of phthalates. Phthalates are widely 
used industrial chemicals that are applied in 
a large variety of commercial products—for 
example, as plasticizers in toys, personal care 
products, and building materials, includ-
ing wall paint (Sathyanarayana et al. 2008; 
Schettler 2006; Wormuth et al. 2006). Thus, 
human exposure is extensive, as demonstrated 
in numerous studies by quantifying phthalate 
metabolites in urine samples from adults and 
children (Becker et al. 2004; Meeker et al. 
2007; Silva et al. 2004). Most human stud-
ies have investigated reproductive effects of 
phthalate exposure, but recent studies also 
indicated thyroid-disrupting effects. Thus, 
serum levels of free thyroxine (T4) and total 
triiodothyronine (T3) in adult men were 
negatively associated with concentrations 
of metabolites of di(2-ethylhexyl) phthalate 
(DEHP) (Meeker et al. 2007). In pregnant 
women urinary concentrations of metabolites 
of di-n-butyl phthalate (DBP) were negatively 
correlated with serum levels of free and total 
T4 (Huang et al. 2007).
The mechanisms of thyroid-disruption may 
be multiple, because experimental studies have 
suggested that phthalates interfere with bind-
ing of T3 to transport proteins (Ishihara et al. 
2003), interacting with the active T3 uptake at 
the plasma membrane (Shimada and Yamauchi 
2004) or exerting antagonistic activity at the 
thyroid receptors (Shen et al. 2009).
Phthalate exposure in children is probably 
higher than in adults when relating intake to 
body weight (Koch et al. 2007). Furthermore, 
the adverse health outcomes due to environ-
mental chemicals may be of greater significance 
in children because appropriate serum levels of 
thyroid hormone and insulin-like growth fac-
tor I (IGF-I) are significant for growth and 
neurological development. In a large cohort 
of children, we aimed to assess the exposure to 
six different diphthalates by measuring their 
metabolites in urine samples. Furthermore, we 
investigated the associations with growth and 
serum levels of thyroid hormones and IGF-I.
Materials and Methods
Study participants and design. A total of 
845 children 4–9 years of age were submit-
ted to thorough clinical examinations between 
January 2006 and August 2007. All children 
had previously participated in a longitudinal 
cohort study, for which 1,953 women were 
included consecutively at their first routine 
obstetric control early in pregnancy at three 
university hospitals in Copenhagen, Denmark. 
Information regarding pregnancy and mater-
nal health was obtained from medical records 
and questionnaires answered by the women. 
Gestational age of the newborn child was based 
on sonography, last menstrual period, and clin-
ical evaluation of the newborn child. In case 
of discrepancies, sonography measurements 
were used. Details of the study have previously 
been published (Chellakooty et al. 2006). The 
children were examined shortly after birth and 
at 3, 18, and 36 months of age by standard-
ized examinations. The length of the newborn 
child was measured supine with a Kiddimeter 
(Raven Equipment Ltd., Essex, UK) to the 
nearest 0.1 cm. All children participating up 
to 3 years of age (n = 1,440) were asked to 
participate in a follow-up study, 902 of whom 
consented. Of these, all children delivering 
a spot urine sample (n = 845) composed the 
present study population. The present study 
comprised measurements of height, weight, 
clinical assessment of pubertal stage (Tanner 
stage), ultrasound of the thyroid gland, includ-
ing calculation of the gland volume (n = 839; 
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Ba c k g r o u n d: Phthalates are widely used chemicals, and human exposure is extensive. Recent 
  studies have indicated that phthalates may have thyroid-disrupting properties.
oB j e c t i v e: We aimed to assess concentrations of phthalate metabolites in urine samples from 
Danish children and to investigate the associations with thyroid function, insulin-like growth 
factor I (IGF-I), and growth.
Me t h o d s : In 845 children 4–9 years of age, we determined urinary concentrations of 12 phthalate 
metabolites and serum levels of thyroid-stimulating hormone, thyroid hormones, and IGF-I.
re s u l t s: Phthalate metabolites were detected in all urine samples, of which monobutyl phtha-
late was present in highest concentration. Phthalate metabolites were negatively associated with 
serum levels of free and total triiodothyronine, although statistically significant primarily in girls. 
Metabolites of di(2-ethylhexyl) phthalate and diisononyl phthalate were negatively associated with 
IGF-I in boys. Most phthalate metabolites were negatively associated with height, weight, body sur-
face, and height gain in both sexes.
co n c l u s i o n s: Our study showed negative associations between urinary phthalate concentrations 
and thyroid hormones, IGF-I, and growth in children. Although our study was not designed to 
reveal the mechanism of action, the overall coherent negative associations between urine phthalate 
and thyroid and growth parameters may suggest causative negative roles of phthalate exposures for 
child health.
key w o r d s : growth, insulin-like growth factor I, phthalate, thyroid. Environ Health Perspect 
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Boas et al. 2009), blood samples (n = 786), and 
spot urine samples. In addition, the parents 
filled in a questionnaire on health and lifestyle.
In the present study, we present infor-
mation on phthalate exposure based on data 
from all children from whom urine samples 
had been collected. For the statistical analyses 
of associations between phthalate concentra-
tions and growth or endocrine measures, we 
excluded all children suffering from diseases 
prone to affect growth or endocrine status 
as well as all children with clinical signs of 
puberty. Thus, a total of 26 children were 
excluded because of heart disease (n = 3), 
brain tumor (n = 1), Langerhans cell histio-
cytosis (n = 1), diabetes (n = 2), epilepsy (n = 
3), cerebral palsy (n = 1), chronic gastrointes-
tinal diseases (n = 2), juvenile arthritis (n = 1), 
pathological thyroid function tests [two with 
thyroid-stimulating hormone (TSH) > 3 SD, 
one with T4 < 3 SD], or puberty (n = 12).
Hormone analyses. Nonfasting peripheral 
venous blood samples were drawn from an 
antecubital vein between midmorning and 
late afternoon. Samples were separated by 
centrifugation and stored at –20°C until anal-
yses. All analyses were carried out blinded for 
the technician and in random order.
TSH and thyroid hormones (T4, free T4, 
T3, and free T3) were measured with an elec-
trochemiluminescence immunoassay (Modular 
Analytics E170; Roche GmbH, Mannheim, 
Germany). Total assay variations for TSH 
were 8.7% and 8.4% at concentrations of 
0.9 and 4.9 mU/L, respectively; T4, 5.6% and 
5.6% at 81 and 167 nmol/L; free T4, 6.0% 
and 8.1% at 12 and 30 pmol/L; T3, 6.7% and 
6.6% at 3.2 and 6.0 nmol/L; and free T3, 
6.4% and 6.4% at 5.3 and 15.0 pmol/L.
IGF-I and insulin-like growth factor bind-
ing protein 3 (IGFBP-3) were measured with 
solid-phase enzyme-labeled chemilumines-
cent immunometric assays (Immulite 2000; 
Diagnostic Products Corp., Los Angeles, 
CA, USA) using World Health Organization 
National Institute for Biological Standards 
and Control International Reference Reagent 
87/518 and 93/560 standards, respectively. The 
limits of detection (LODs) were 20 and 0.1 
μg/mL, respectively. Intraassay variations were 
< 2.1% and 4.4%, respectively; and interassay 
variations were < 8.9% and 5.6%, respectively.
Urinary phthalate metabolite analyses. 
Spot urine samples were collected in polyeth-
ylene cups and stored as 10-mL aliquots in 
20-mL glass scintillation vials with tops packed 
with aluminum foil at –20°C. Urine samples 
were analyzed for concentrations of 12 differ-
ent phthalate metabolites by liquid chroma-
tography (LC) tandem mass spectrometry with 
preceding enzymatic deconjugation followed by 
solid phase extraction. The method for prepara-
tion of samples, standard solutions, and quality 
controls as well as the instrumental analysis 
was previously described (Janjua et al. 2008) 
and used with the following modifications. 
The solvents for LC separation were as follows: 
A, 0.1% acetic acid in water; B, 0.1% acetic 
acid in acetonitrile. Solvent programming was 
0.0–1.5 min, 5% B; 1.6 min, 27% B; 6.0 min, 
30% B; 6.1–10.0 min, 45% B; 10.1 min, 70% 
B; 12.0–15.5 min, 90% B; 15.6–17.0 min, 
5% B. For all analytes, the retention time on 
column was 6.55–13.14 min, and a good sepa-
ration was obtained. The precursor and product 
ions (mz) were as previously described (Silva 
et al. 2007). The calibration curve range was 
0.5–500 ng/mL. Method accuracy and preci-
sion were validated by repeating (n = 5) intra-
day analysis of pooled urine samples spiked 
with native phthalate standards (5, 10, and 
50 ng/mL) and by repeating interday analysis 
of control urine samples spiked with low and 
high concentrations (n = 24 over a 2-month 
period). Mean (± SD) recovery ranged from 
88% ± 8.6% to 108% ± 4.5%, and interday 
variation was < 10% for most analytes. LODs 
were calculated as previously described (Blount 
et al. 2000) and are listed in Table 1. All urine 
samples with extremely high concentrations of 
phthalate metabolites were reanalyzed to con-
firm the values.
We analyzed the following metabolites: 
monoethyl phthalate (MEP) from diethyl 
phthalate (DEP); mono-n-butyl phthalate and 
monoisobutyl phthalate (MBP; analyzed as 
one compound) from di-n-butyl and DBP; 
monobenzyl phthalate (MBzP) from butyl 
benzyl phthalate; mono-(2-ethylhexyl) phtha-
late (MEHP), mono(2-ethyl-5-hydroxyhexyl) 
phthalate (MEHHP), mono(2-ethyl-5-oxo-
hexyl) phthalate (MEOHP), and mono(2-
ethyl-5-carboxypentyl) phthalate (MECPP) 
from DEHP; mono-n-octyl phthalate (MOP) 
from di-n-octyl phthalate; and monoisononyl 
phthalate (MiNP) and monocarboxyisooctyl 
phthalate (MCiOP) from diisononyl phthalate 
(DiNP). In 250 randomly selected samples 
(125 girls, 125 boys), two additional secondary 
metabolites of DiNP were measured: mono-
hydroxyisononyl phthalate (MHiNP) and 
monooxoisononyl phthalate (MOiNP). In 
samples from 100 randomly selected children, 
the content of both free and total (sum of 
free and conjugated) phthalate metabolites 
was determined, and the ratio was calculated 
(concentration of free/concentration of total 
phthalate metabolites).
Urinary iodine and creatinine analyses. 
Because low or high serum levels of iodine are 
known to affect thyroid function, the overall 
iodine status of the population was estimated 
by quantifying the iodine (127I) concentration 
in 250 randomly selected urine samples using 
an inductively coupled plasma mass spec-
trometer (Agilent Technologies, Waldbron, 
Germany) after dilution by an aqueous solu-
tion containing tetramethylammonium 
hydroxide. LOD was 0.1 μg/L. Recovery of 
iodine (mean ±SD) was 103 ± 3% (n = 13). 
Creatinine was determined in all urine sam-
ples by colorimetric enzymatic assay.
Table 1. Sex-specific phthalate metabolite concentrations (μg/L and μg/g creatinine) in spot urine sam-
ples from 845 Danish children 4–9 years of age (examined 2006–2007).
Phthalate 
metabolite 
Percent 
> LOD
Male Female
LOD Median GM Min 25% 75% Max Median GM Min 25% 75% Max
Uncorrected concentration (μg/L)
MEP 0.24 100 21 21 0.6 11 39 731 21 21 1.1 10 44 684
MBP 3.94 100 130 124 12 75 207 6,457 121 114 9.0 63 216 1,217
MBzP 1.26 86 17 2.8 0.0 6.2 37 4,548 12 0.5 0.0 3.3 31 272
MEHP 0.31 99 4.5 4.1 0.0 2.5 7.7 78 3.6 3.6 0.0 1.8 7.2 231
MEHHP 0.60 100 37 33.2 1.0 19 64 1,718 31 28 1.3 14 55 1,672
MEOHP 0.14 100 19 17 0.5 9.6 32 656 16 15 0.6 7.8 29 734
MECPP 0.43 100 30 29 1.0 16 52 676 27 27 1.7 14 49 1,755
MOP 0.04 16 0.0 0.0 0.0 0.0 0.0 11 0.0 0.0 0.0 0.0 0.0 11
MiNP 0.62 49 0.6 1.1 0.0 0.0 1.8 1,100 0.5 1.1 0.0 0.0 1.7 61
MHiNPa 0.31 98 6.6 5.8 0.1 3.3 11 793 4.9 4.5 0.0 2.1 8.2 400
MOiNPa 0.16 99 3.4 2.9 0.0 1.7 5.1 312 2.7 2.3 0.1 1.3 4.1 188
MCiOP 0.08 100 7.2 7.3 0.3 4.1 12 2,063 6.5 6.3 0.3 3.5 12 598
Creatinine-corrected concentration (μg/g creatinine)
MEP 31 34 5.7 20 52 791 36 40 7.6 22 65 526
MBP 191 199 47.5 140 276 4,940 227 221 39 157 312 1,365
MBzP 26 25 0.0 10 49 2,916 20 22 0.0 6.9 42 474
MEHP 6.8 6.9 0.0 4.1 11 210 6.7 7.2 0.0 4.1 12 186
MEHHP 52 53 4.9 33 84 1,818 52 55 7.3 36 81 1,220
MEOHP 26 27 2.6 17 42 794 28 29 3.5 18 41 536
MECPP 43 46 6.5 29 68 1,648 49 51 8.2 33 75 1,280
MOP 0.0 0.0 0.0 0.0 0.0 10 0.0 0.0 0.0 0.0 0.0 11
MiNP 1.0 1.7 0.0 0.0 2.7 1,194 1.1 2.0 0.0 0.0 3.3 45
MHiNPa 8.4 8.9 1.6 5.5 14 754 7.4 7.6 0.0 4.9 9.9 292
MOiNPa 4.1 4.4 0.0 2.8 6.2 296 3.9 3.9 0.2 2.6 5.2 137
MCiOP 10 12 1.9 6.9 18 2,241 12 12 1.4 7.5 18 574
Abbreviations: 25%, 25th percentile; 75%, 75th percentile; GM, geometric mean; Max, maximum; Min, minimum.
aMeasured in only 250 randomly selected samples.Boas et al.
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Statistical analyses. Statistical analy-
ses were performed with SPSS (version 17; 
SPSS, Inc., Chicago, IL, USA). Body surface 
area (BSA) was calculated using the DuBois 
formula: BSA (m2) = 0.007184 × height 
(cm)0.725 × weight (kg)0.425. Standard devia-
tion scores (SDSs) of height, weight, body 
mass index (BMI), and BSA were calculated 
based on reference material from Danish 
children (Andersen et al. 1982; Nysom et al. 
2001). Midparental height SDS (HSDSmidpar) 
was calculated as the mean height SDS of both 
parents. To estimate the difference between 
expected and observed height, we also calcu-
lated the difference between child and mid-
parental height SDS (DiffHSDSmidpar), the 
change in height SDS between 0 and 3 years 
(ΔHSDS0–3) and between 1.5 years and the 
current examination (ΔHSDSchildhood).
Log transformation was applied to phtha-
late concentrations, phthalate ratios, TSH, 
IGF-I, IGFBP-3, and thyroid volume to 
improve the approximation of normal dis-
tribution. Statistical analyses included only 
phthalate metabolites measurable in more 
than 50% of children. For phthalate metabo-
lite levels below the LOD, LOD divided by 
the square root of 2 was used. We calculated 
the sum of concentrations of DEHP metab-
olites (MEHP, MEHHP, MEOHP, and 
MECPP, corrected for molecular weights). 
To estimate associations with the combined 
phthalate exposure, we calculated a total 
phthalate score: Concentrations of each of 
the metabolites MEP, MBP, MBzP, MCiOP, 
and the sum of DEHP metabolites were 
divided into quartiles, and the total phthalate 
score was the sum of quartiles 0–3 (range, 
0–15). Because evidence on dose–response 
relationships between phthalates and thy-
roid hormone levels is sparse (Hinton et al. 
1986; O’Connor et al. 2002), the metabo-
lites concerned were equally weighted in the 
  calculation of the score.
We calculated the percentage of DEHP 
excreted as MEHP (MEHP%): MEHP con-
centration divided by the sum of all DEHP 
metabolite concentrations (MEHP, MEHHP, 
MEOHP, MECPP) × 100 (all concentrations 
were converted to nanomoles per milliliter). 
For samples with concentrations above LOD, 
the ratios between free and total metabolite 
concentrations were calculated.
We used parametric correlation analyses 
and the t-test to investigate associations between 
phthalate metabolite levels, age, body size, and 
SDS for anthropometric variables as well as sex 
differences. Multivariate linear regression was 
used to explore relationships between phthalate 
metabolite concentrations and serum hormone 
levels or growth estimates, including sex and 
age as covariates in analyses of hormone levels, 
and in addition HSDSmidpar and birth length in 
analyses of growth estimates.
Because urine was collected as spot sam-
ples, phthalate concentrations were adjusted 
for dilution by either dividing with the crea-
tinine concentration or including the square 
root of creatinine concentrations in regres-
sion analyses. These two approaches yielded 
comparable estimates, so creatinine-corrected 
data represent phthalate divided by creatinine 
concentration. All statistical analyses were 
performed both with crude and creatinine-
corrected phthalate concentrations. p-Values 
< 0.05 were considered statistically significant.
Ethical aspects. Parents gave informed 
consent for the participation of their child. 
The study was performed according to the 
Helsinki II Declaration and was approved by 
the local ethics committee and the Danish 
Registry Agency.
Results
Clinical characteristics of the 845 participat-
ing children are shown in Table 2. All urine 
samples contained measurable amounts of 
metabolites of DEP, DBP, DEHP, and DiNP. 
Table 2. Clinical characteristics of the population [mean ± SD or n (%)].
Characteristic Total (n = 845) Males (n = 503) Females (n = 342)
Age (years) 7.0 ± 1.3 6.9 ± 1.4 7.1 ± 1.1
Birth weight (kg) 3.5 ± 0.6 3.6 ± 0.6 3.5 ± 0.6
Birth length (cm) 50.8 ± 2.6 51.2 ± 2.6 50.4 ± 2.5
Gestational age (days) 278.8 ± 13.2 279.2 ± 12.6 278.3 ± 14.0
WGA (%) –0.6 ± 12.9 –0.8 ± 12.7 –0.2 ± 13.3
Height (cm) 124.5 ± 9.5 124.4 ± 10.1 124.7 ± 8.6
Weight (kg) 24.7 ± 5.4 24.6 ± 5.6 24.9 ± 4.9
BMI (kg/m2) 15.8 ± 1.7 15.7 ± 1.6 15.9 ± 1.8
BSA (m2) 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1
Thyroid volume (mL) 3.1 ± 1.0 3.1 ± 1.1 3.1 ± 0.9
Urinary creatinine (g/L) 0.7 ± 0.4 0.7 ± 0.4 0.7 ± 0.4
Urinary iodine (μg/L) 216.4 ± 126.6 232.6 ± 131.5 200.4 ± 119.9
Corrected urinary iodine (μg/g creatinine) 328.7 ± 177.7 337.8 ± 178.2 319.7 ± 177.5
Maternal parity [n (%)]
1 524 (62) 317 (63) 207 (61)
2 247 (29) 143 (28) 104 (31)
> 2 72 (9) 43 (9) 29 (8)
Outcome
Singletons 803 (95) 478 (95) 325 (95)
Twins 42 (5) 25 (5) 17 (5)
WGA, weight for gestational age, given as percent deviation from expected mean weight for gestational age.
Table 3. Regression analyses (adjusted for age and sex) of associations between phthalate metabolites 
and total T3, free T3, and IGF-I in prepubertal Danish children (n = 758).
Crude analysis Creatinine-corrected analysis
All Boys Girls All Boys Girls
Outcome B p-Value B p-Value B p-Value B p-Value B p-Value B p-Value
Total T3
MEP –0.06 0.015* –0.01 0.829 –0.12 0.001* –0.02 0.605 0.05 0.262 –0.11 0.026*
MBP –0.09 0.005* –0.06 0.143 –0.14 0.007* –0.01 0.873 –0.01 0.875 –0.02 0.780
MBzP –0.05 0.016* –0.04 0.150 –0.06 0.041* –0.03 0.266 –0.03 0.412 –0.03 0.436
MCiOP –0.07 0.017* –0.07 0.060 –0.06 0.142 –0.01 0.837 –0.04 0.347 0.06 0.345
ΣDEHP –0.04 0.170 0.00 0.950 –0.10 0.022* 0.06 0.153 0.09 0.082 0.00 0.965
Phthalate 
score
–0.01 0.018* 0.00 0.518 –0.01 0.003* 0.00 0.769 0.00 0.630 0.00 0.773
Free T3
MEP –0.13 0.013* –0.08 0.253 –0.18 0.013* 0.00 0.986 0.10 0.310 –0.14 0.179
MBP –0.21 0.002* –0.26 0.004* –0.15 0.141 0.03 0.785 –0.09 0.517 0.15 0.325
MBzP –0.08 0.032* –0.08 0.137 –0.09 0.120 –0.02 0.710 –0.01 0.883 –0.03 0.643
MCiOP –0.18 0.002* –0.21 0.005* –0.12 0.144 –0.04 0.580 –0.09 0.300 0.06 0.648
ΣDEHP –0.15 0.011* –0.13 0.107 –0.19 0.030* 0.04 0.626 0.08 0.460 –0.05 0.689
Phthalate 
score
–0.01 0.006* –0.01 0.061 –0.02 0.038* 0.00 0.562 0.00 0.844 0.00 0.662
IGF-I
MEP –0.01 0.213 –0.01 0.479 –0.02 0.292 –0.01 0.559 0.00 0.921 –0.02 0.309
MBP –0.01 0.671 –0.01 0.536 0.00 0.961 0.02 0.336 0.02 0.574 0.03 0.427
MBzP –0.01 0.383 –0.02 0.170 0.00 0.796 0.00 0.737 –0.01 0.321 0.01 0.510
MCiOP –0.04 0.003* –0.04 0.006* –0.03 0.153 –0.04 0.006* –0.05 0.020* –0.04 0.137
ΣDEHP –0.03 0.014* –0.05 0.002* 0.00 0.816 –0.04 0.034* –0.07 0.003* 0.01 0.798
Phthalate 
score
0.00 0.027* 0.00 0.011* 0.00 0.639 0.00 0.307 0.00 0.106 0.00 0.769
Abbreviations: B, regression coefficient; ΣDEHP, sum of concentrations of all measured DEHP metabolites corrected for 
molecular weights.
*p < 0.05.Phthalates, growth, and thyroid function
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Distributions of crude and creatinine-corrected 
concentrations of phthalate metabolites are 
presented in Table 1. Crude concentrations of 
all phthalate metabolites were positively associ-
ated with each other, and creatinine-corrected 
concentrations also were positively associated 
with each other (p < 0.01 in all cases). Samples 
from six children contained extremely high 
concentrations of MBP (one boy, 6,456 μg/L), 
MBzP (one boy, 4,547 μg/L), DEHP metabo-
lites (MEHHP; one girl and one boy, 1,671–
1,717 μg/L), or DiNP metabolites (two boys: 
MCiOP, 2,063 μg/L; MHiNP, 792 μg/L). 
Concentrations remained high after correcting 
for creatinine.
Boys presented significantly higher urine 
concentrations of MBzP, MEHP, MEHHP, 
MEOHP, and MCiOP (p < 0.05 in all cases) 
than did girls. However, when corrected for 
creatinine, concentrations of MEP, MBP, 
and MECPP were higher in girls (p < 0.05), 
whereas the concentrations of MBzP, MHiNP, 
and MCiOP remained highest in boys 
(p < 0.05 in all cases). In correlation analyses, 
all phthalate metabolites were negatively asso-
ciated with absolute values of height, weight, 
BMI, and BSA, reaching significance for MEP, 
MEOHP, MECPP, sum of DEHP metabo-
lites, and total phthalate score (r = –0.097 to 
–0.074; p < 0.05). Only MBzP was negatively 
(r = –0.077; p = 0.025) correlated with age. 
When corrected for creatinine, all phthalate 
metabolites were negatively correlated with age 
(r = –0.210 to –0.106; p < 0.005 in all cases).
In the analyses of associations between 
phthalate concentrations and endocrine or 
growth measures, differences in results for 
boys and girls were generally within ranges 
consistent with random variation, but some 
estimates were statistically significant in only 
one group. In boys, phthalate metabolites 
were in general negatively associated with total 
and free T3, but few reached statistical sig-
nificance (Table 3) [all confidence intervals are 
listed in Supplemental Material, Tables 1–3 
(doi:10.1289/ehp.0901331)]. However, 
associations became nonsignificant when 
correcting phthalate concentrations with crea-
tinine. We found no consistent associations 
with TSH, T4, or free T4 (see Supplemental 
Material, Tables 1 and 2). IGF-I was nega-
tively associated with crude DEHP metabo-
lites and MCiOP (Table 3, Figure 1), and 
IGFBP-3 with DEHP metabolites (p < 0.05). 
We found significantly negative associations 
between recent height gain (ΔHSDSchildhood) 
and both crude and creatinine-corrected 
DEHP metabolite concentrations (p < 0.05) 
(see Supplemental Material, Table 3). All 
other associations between ΔHSDSchildhood, 
IGF-I, IGFBP-3, and phthalate metabolites 
were similarly negative but not significantly. 
We found no consistent associations with cur-
rent height (HSDS or DiffHSDSmidpar).
In girls, all associations between periph-
eral thyroid hormones and unadjusted 
phthalate metabolites were negative, reach-
ing significance for total T3 with most phtha-
late metabolites, for free T3 with MEP and 
DEHP metabolites (Table 3), and for total 
T4 with MEP (B = –5.19, p = 0.013) and 
total phthalate score (B = –0.48, p = 0.037) 
[Supplemental Material, Table 1 (doi:10.1289/
ehp.0901331)]. IGF-I was not significantly 
associated with unadjusted phthalate metabo-
lites (Table 3), but IGFBP-3 was significantly 
negatively associated with DEHP metabolites 
and MCiOP (p < 0.05) (see Supplemental 
Material, Table 2). We found significantly 
negative correlations between current height 
(HSDS or DiffHSDSmidpar) and most crude 
phthalate metabolites as well as the phthalate 
score (see Supplemental Material, Table 3). 
Early height gain (ΔHSDS0–3) was negatively 
associated with MCiOP. When correcting for 
creatinine, only a few associations with thyroid 
hormones remained significant. For growth 
estimates, most significant associations became 
nonsignificant, whereas several associations 
with recent height gain (ΔHSDSchildhood) 
became significant (see Supplemental Material, 
Table 3).
When analyzing boys and girls together, 
unadjusted phthalate metabolites showed sig-
nificant negative associations with T3, free T3, 
and IGF-I (Figures 1 and 2, Table 3). The 
associations with IGF-I, but not with thyroid 
hormones, remained significant after correction 
for urinary creatinine [Supplemental Material, 
Figure 1 (doi:10.1289/ehp.0901331)]. Current 
growth measures (HSDS, DiffHSDSmidpar and 
ΔHSDSchildhood) were significantly negatively 
associated with most DEHP metabolites and 
their sum, for both crude and creatinine-
  corrected concentrations (see also Supplemental 
Material, Table 3). Thyroid volume ranged 
from 1.0 to 6.8 mL and demonstrated no sta-
tistically significant sex difference. In neither 
boys nor girls was thyroid volume SDS associ-
ated with concentrations of phthalate metabo-
lites (data not shown).
Mean ± SD MEHP% was 5.9 ± 2.7%. 
MEHP% was positively correlated with 
weight (r = 0.072, p = 0.039) and BSA (r = 
0.072, p = 0.040) and negatively associated 
with T4 (r = –0.077, p = 0.034) and creati-
nine (r = –0.141, p < 0.001). Median ratios 
between free and total phthalate metabolite 
concentrations ranged from < 0.1 (MBP, 
MEHHP, MEOHP, MHiNP) to 0.6–0.8 
Figure 1. Regression coefficients (95% confidence intervals) for a change in total T3 (ΔT3) associated with 
quintiles of MEP, MCiOP, MBP, MBzP, and sum of DEHP metabolite concentrations (ΣDEHP) (adjusted for 
sex and age; n = 758).
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(MEP, MECPP, MCiOP). Ratios correlated 
positively with each other (p ≤ 0.001 in all 
cases) and negatively with age (significant for 
MEP, MEOHP, and MHiNP) and body size.
Urinary concentration of creatinine was 
significantly positively associated with age, 
height, weight, and BSA (p ≤ 0.001 in all 
cases), and boys had higher levels of urinary 
creatinine than did girls (p = 0.001). Seventy-
three urine samples were very dilute, with a 
creatinine concentration < 0.2 g/L. When 
excluding these samples from the statistical 
analyses, most associations between phtha-
late metabolites and total and free T3 became 
insignificant, although they remained negative 
(data not shown).
Median iodine concentration was 
192.0 μg/L (282.3 μg I/g creatinine), and the 
20th percentile was 115.9 μg/L. Thus, the sub-
group of children tested was iodine sufficient 
according to World Health Organization cri-
teria (World Health Organization et al. 2007). 
We repeated all the above analyses with inclu-
sion of children with diseases or with exclu-
sion of children born prematurely (n = 54) or 
small for gestational age (n = 40) and children 
with extremely high urinary concentrations 
of phthalate metabolites (n = 6). This did not 
change the overall pattern of associations. In 
extended versions of the regression analyses 
demonstrated in Table 3, we added interac-
tion variables between phthalate metabolites 
and sex. In these analyses, associations between 
hormone levels and both phthalate levels and 
the interaction variable were generally nonsig-
nificant, suggesting that estimates for boys and 
girls combined were valid estimates of effect 
and that the differences in estimates that we 
observed between boys and girls were generally 
consistent with random variation. However, 
we cannot rule out sex-specific effects in our 
study population because we had limited 
power to assess them. Phthalate concentrations 
in samples from the three excluded children 
with aberrant thyroid hormone concentrations 
were within the observed ranges in the rest of 
the children.
Discussion
In this comprehensive study of phthalate 
exposure and health effects in children, we 
determined urinary excretion of 12 phthalate 
metabolites in 845 iodine-sufficient Danish 
children 4–9 years of age and related phtha-
late exposure measures to thyroid function 
and growth. The concentrations of phthalate 
metabolites were largely comparable to levels 
previously reported from other studies of chil-
dren (Becker et al. 2004; Koch et al. 2007; 
Sathyanarayana et al. 2008; Silva et al. 2004; 
Wolff et al. 2007), except for relatively low 
levels of MEP: The geometric mean of MEP 
in our study group was 21 μg/L, in contrast 
to 91 and 177 μg/L in American studies of 
children (Silva et al. 2004; Teitelbaum et al. 
2008). Levels of MBP were higher in Danish 
children than in studies from the United 
States (Sathyanarayana et al. 2008; Silva et al. 
2004; Wolff et al. 2007) but comparable to 
levels in young adults in Sweden (Jonsson 
et al. 2005) and children in Germany (Koch 
et al. 2007). This may indicate regional differ-
ences in exposure.
Overall, urinary phthalate concentrations 
were negatively associated with thyroid hor-
mones and IGF-I as well as with childhood 
growth. In some cases results were statistically 
significant in girls but not in boys, or vice versa. 
In girls, crude concentrations of phthalate 
metabolites were negatively associated with total 
and free T3, thus potentially reflecting an effect 
of phthalates on thyroid function. In boys, these 
associations were not as consistent, although the 
overall trend was also negative. Adverse effects 
of phthalates on peripheral thyroid hormones 
are supported by results from two other epide-
miological studies (Huang et al. 2007; Meeker 
et al. 2007). Thus, a study of pregnant women 
found an inverse association between MBP and 
T4 and free T4 (Huang et al. 2007), whereas 
a study of adult men reported negative asso-
ciations between MEHP and free T4 and T3 
(Meeker et al. 2007). Evidence from animal 
studies is sparse, but in rats exposed to DBP 
(O’Connor et al. 2002) and DEHP (Hinton 
et al. 1986) peripheral thyroid hormones were 
reduced, and several studies found reduced thy-
roid weight and histopathology indicating thy-
roid hyperactivity (smaller follicles, increased 
number, size, and iodine content of lysosomes) 
after phthalate exposure (Howarth et al. 2001; 
Poon et al. 1997). However, in view of the very 
complex and multifactorial regulation of thy-
roid size (Hansen et al. 2004), it is not surpris-
ing that the changes in phthalate concentrations 
were not reflected by thyroid size alterations in 
our population.
Our results also revealed associations of 
phthalates with IGF-I in children. Few previ-
ous studies have directly addressed the effect 
of endocrine-disrupting chemicals on the 
growth hormone (GH)/IGF-I axis. Studies 
of IGF-I effects indicated that prenatal expo-
sure to DBP or DEHP may lead to induc-
tion of IGF-I mRNA in reproductive tissues 
(Bowman et al. 2005; Lin et al. 2008), reflect-
ing a lowering of IGF-I levels. Additionally, 
phthalates may potentially interact with other 
endocrine pathways, such as the hypotha-
lamic–pituitary axis or androgen biosynthe-
sis. Such complex in vivo effects might be 
expected to contribute to differences in effects 
according to sex. Antiandrogenic drugs may 
reduce IGF-I (Juul et al. 1995), and because 
studies have shown phthalates to have anti-
androgenic properties (Gray et al. 2000), 
phthalates may consequently interfere with 
IGF-I levels. Moreover, the GH/IGF-I axis 
is known to stimulate the activity of periph-
eral deiodinases, converting T4 to the biologi-
cally active T3 (Hussain et al. 1996; Jorgensen 
et al. 1989). Thus, an effect on IGF-I may 
indirectly reduce serum levels of T3.
Growth rate and anthropometric mea-
surements such as height, weight, and BSA 
showed overall negative associations with uri-
nary concentrations of phthalate metabolites, 
consistent with an adverse effect of phthalates 
on growth. In support, animal studies have 
shown negative associations between prenatal 
phthalate exposure and birth weight (Tanaka 
2005; Tyl et al. 2004) as well as gain of body 
weight (Fukuwatari et al. 2002), although 
conflicting data have been reported (Arcadi 
et al. 1998; Sharpe et al. 1995). In contrast to 
these studies, and to the common hypothesis 
Figure 2. Regression coefficients (95% confidence intervals) for a change in IGF-I associated with quin-
tiles of MCIOP and sum of DEHP metabolite (ΣDEHP) concentrations in boys (n = 470) and girls (n = 297) 
(adjusted for age). 
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of phthalates causing impaired fetal growth, 
Wolff et al. (2008) showed a positive asso-
ciation between phthalates of low molecular 
weight and duration of pregnancy and infant 
head circumference. 
In our comprehensive study, we per-
formed numerous association tests between 
a large number of outcome measures and 
12 different phthalate metabolites. Clearly, 
such multiple significance testing implies a 
risk of obtaining “false-positive” results by 
chance. We therefore focused our interpreta-
tion of the results on overall trends and not 
on single significant associations. Thyroid hor-
mones and growth factors are closely linked 
with each other and contribute significantly in 
the regulation of childhood growth. Thus, our 
observation of associations between phthalate 
exposure and growth supports the conclu-
sion that phthalate exposure in this age group 
exerts an adverse biological effect.
However, words of caution appear neces-
sary with regard to assessment of phthalate 
exposure. We collected spot urine samples, the 
concentrations of which will depend on recent 
fluid intake. Previous reports have attempted 
to correct, at least partly, for dilution by mea-
suring urinary creatinine concentrations or 
specific gravity. However, the excretion of crea-
tinine in children is strongly correlated with 
age and anthropometric variables as height, 
weight, and BSA (Skinner et al. 1996), as also 
seen in our study. In addition, there is a sex 
difference, with boys having higher excretion 
of creatinine compared with girls (Skinner 
et al. 1996). Thus, sex and anthropometric 
features per se may affect the level of the cor-
rection factor (creatinine). Consequently, when 
correcting phthalate concentrations by divid-
ing by creatinine, corrected phthalate values 
will tend to decrease with age and body size, 
thus mimicking a negative association between 
phthalate levels and growth parameters. Such 
an interaction has also been demonstrated 
in a study of maternal urinary phthalate lev-
els and the associations with infant outcome 
(Wolff et al. 2008). In contrast, associations 
with parameters declining with age, such as 
peripheral thyroid hormones in childhood, will 
tend to become more positive, which may be 
the case for the associations seen with thyroid 
hormones in our study.
Not only creatinine but also renal glom-
erular filtration rate and thus urinary volume 
are influenced by age, anthropometry, thy-
roid hormones (Iglesias and Diez 2009), and 
IGF-I (Feld and Hirschberg 1996). Thus, 
large and fast-growing children with high 
levels of thyroid hormones and IGF-I have a 
higher probability of large urinary volumes 
and consequently lower crude urinary concen-
trations of phthalate metabolites than do small 
children being exposed to the same amount 
of phthalates. Furthermore, small children 
may be exposed to higher levels of phthalates 
relative to body size (Wittassek and Angerer 
2008), because small children have a higher 
food intake as well as a higher body surface per 
kilogram of body weight. Hence, the negative 
associations between urinary phthalate con-
centrations and body size or height gain may 
partly be explained by physiological mecha-
nisms resulting in reverse causality. In order 
to adjust for the interaction between creati-
nine and outcome, other studies (Adibi et al. 
2009) included the square root of creatinine. 
However, in our study, the application of this 
correction modus did not significantly change 
the statistical estimates and overall results.
Reservations should also be stated in rela-
tion to the fact that we collected only a single 
urine sample from each child, which may not 
be representative for their average exposure, 
although several studies concluded that a single 
urine sample could be moderately predictive of 
individual exposure over a couple of months 
(Hauser et al. 2004; Teitelbaum et al. 2008).
One previous study suggested that 
MEHP% may be a phenotypic marker of 
DEHP metabolism and excretion (Hauser 
2008; Meeker et al. 2007). MEHP% was posi-
tively associated, and the fraction of free phtha-
late metabolites negatively associated, with age 
and anthropometric measurements, so it seems 
that age and body size may affect phthalate 
metabolism, both oxidation and glucuronida-
tion. Other studies have found similar relations 
between hydrolyzed and oxidized metabolites 
(Becker et al. 2004). Interestingly, MEHP% 
was negatively associated with T4 in our mate-
rial, which has also been reported in a previous 
study (Meeker et al. 2007). Thus, thyroid hor-
mones may have an accelerating effect on the 
metabolism of phthalates.
Conclusions
Our study showed negative associations 
between urinary phthalate concentrations 
and thyroid hormones, IGF-I, and growth in 
healthy children. Although our study was not 
designed to reveal the mechanism of action, the 
overall coherent negative associations between 
urine phthalate and thyroid and growth param-
eters may suggest causative negative roles of 
phthalate exposures for child health.
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